---
title: "Altimmune CEO Jerome Benedict Durso acquires USD 44,250 in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295838846.md"
description: "Altimmune CEO Jerome Benedict Durso purchased 15,000 common shares at $2.95 each, totaling USD 44,250. This transaction increased his directly held stake to 62,500 shares."
datetime: "2026-08-13T20:06:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295838846.md)
  - [en](https://longbridge.com/en/news/295838846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295838846.md)
generator: "portal-rs"
---

# Altimmune CEO Jerome Benedict Durso acquires USD 44,250 in common shares

-   Altimmune President and CEO Jerome Benedict Durso bought 15,000 common shares at $2.95. \* Directly held stake rose to 62,500 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001698665-26-000007), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md)
- [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md)
- [LG Electronics deepens robotics collaboration with Nvidia](https://longbridge.com/en/news/296171747.md)
- [09:15 ETSEC's Proposed E-Delivery Rule Signals a New Era in Customer Communications](https://longbridge.com/en/news/296361991.md)
- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**